Sign In
Buy SIBN
$15.84
+0.630 (+4.14%)
At Close: Jun 18, 2026
AXQ Capital LP Invests $290,000 in SiBone $SIBN
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP acquired a new stake in shares of SiBone (NASDAQ: SIBN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SE
SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
04:09pm, Tuesday, 18'th Nov 2025
SANTA CLARA, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti
Reviewing SiBone (NASDAQ:SIBN) & Spectral Diagnostics (OTCMKTS:EDTXF)
03:58am, Saturday, 15'th Nov 2025
Spectral Diagnostics (OTCMKTS:EDTXF - Get Free Report) and SiBone (NASDAQ: SIBN - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two co
Why SI-Bone Stock Was Crushing It Today
03:02pm, Tuesday, 11'th Nov 2025
The medical device maker posted a satisfying beat-and-raise third quarter. During the period, it managed to narrow its net loss considerably.
SI-BONE, Inc. (SIBN) Q3 2025 Earnings Call Transcript
08:11pm, Monday, 10'th Nov 2025
SI-BONE, Inc. ( SIBN ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Saqib Iqbal - Director of FP&A and Investor Relations Laura Francis - CEO & Director Anshul Maheshwari -
Si-Bone (SIBN) Reports Q3 Loss, Beats Revenue Estimates
07:56pm, Monday, 10'th Nov 2025
Si-Bone (SIBN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.16 per share a year ago.
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2025 and Raises 2025 Guidance
04:09pm, Monday, 10'th Nov 2025
Delivered ~21% worldwide revenue growth, ~5% adjusted EBITDA margin, and positive cash from operating activities in the quarter
Impax Small Cap Fund Q3 2025 Contributors And Detractors
04:26pm, Tuesday, 28'th Oct 2025
Ligand Pharmaceuticals (LGND) (Health Care, Pharmaceuticals) shares rose after announcing adjusted earnings per share that came in ahead of consensus. Acadian Asset Management (AAMI) (Financials, Asse
SI-BONE To Report Third Quarter 2025 Financial Results on November 10, 2025
04:09pm, Monday, 20'th Oct 2025
SANTA CLARA, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial resul
NEWTOWN, Pa., Oct. 03, 2025 (GLOBE NEWSWIRE) -- The law firm of Edelson Lechtzin LLP is investigating data privacy claims regarding an incident at SI-Bone, Inc. (“SI-Bone”).
SI-BONE, Inc. (SIBN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
11:51am, Tuesday, 09'th Sep 2025
SI-BONE, Inc. (NASDAQ:SIBN ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:00 AM EDT Company Participants Laura Francis - CEO & Director Anshul Maheshwari - Chief Financi
SI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025
04:03pm, Tuesday, 26'th Aug 2025
SANTA CLARA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be parti
SI-BONE, Inc. (SIBN) Q2 2025 Earnings Call Transcript
01:50am, Tuesday, 05'th Aug 2025
SI-BONE, Inc. (NASDAQ:SIBN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Anshul Maheshwari - Chief Financial Officer Laura A. Francis - CEO & Director Saqib Iqbal -
Si-Bone (SIBN) Reports Q2 Loss, Beats Revenue Estimates
06:47pm, Monday, 04'th Aug 2025
Si-Bone (SIBN) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.22 per share a year ago.
SI-BONE, Inc. Reports Financial Results for the Second Quarter 2025 and Raises 2025 Guidance
04:09pm, Monday, 04'th Aug 2025
Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven Achieved ~22% worldwide revenue growth, positive Adjusted EBITDA and cash flow breakeven
